Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
Gyre Therapeutics, Inc. (GYRE)
Company Research
Source: Yahoo! Finance
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. By way of learning-by-doing, we'll look at ROE to gain a better understanding of Gyre Therapeutics, Inc. ( NASDAQ:GYRE ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How To Calculate Return On Equity? ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Gyre Therapeutics is: 8.6% = US$12m ÷ US$137m (Based on the trailing twelve months to September 2025). The 'return' is the yearly profit. So, this means that for every
Show less
Read more
Impact Snapshot
Event Time:
GYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GYRE alerts
High impacting Gyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GYRE
News
- Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA MeetingGlobeNewswire
- Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business UpdateGlobeNewswire
GYRE
Earnings
- 11/7/25 - Miss
GYRE
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/5/26 - Form 8-K
- GYRE's page on the SEC website